Executive Vice President, U.S. Commercial
Christine (Chris) Fox was appointed Executive Vice President, U.S. Commercial on November 20, 2023, leading all commercial activities for Teva in the U.S., including our generics, biosimilars and innovative medicines business.
Chris brings more than 30 years of healthcare industry experience with leadership roles in sales, marketing, and commercial operations, responsible for teams ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas.
Prior to Teva, Chris served as President at Novartis Gene Therapies since December 2021. Previously, Chris was vice president and general manager for the Bone, Cardiometabolic and Nephrology business for Amgen. She also served as the general manager of the company’s United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda, and several startups.